Financials Appendix 1 Unaudited pro-forma consolidated income statement For the year ended 31 March 2011 Year ended Year ended 31 March 31 March 2011 2010 m m Royalties 70.0 64.2 Marketed products 35.4 34.3 Biocompatibles 33.9 26.9 Revenue 139.3 125.4 Cost of sales: royalties 22.4 17.6 Cost of sales: marketed products 8.8 15.2 Biocompatibles 7.7 5.6 Gross profit 100.4 87.0 Operating expenses: foreign exchange losses 1.7 4.0 Operating expense : other 52.4 39.4 Operating expenses: total 54.1 43.4 Research and development 41.8 40.5 Profit on disposal of assets and investments 1.5 1.1 Amounts written off associates and investments 1.4 Operating profit 4.6 4.2 Financial income 3.5 7.7 Financial expense 0.2 0.3 Profit before tax 7.9 11.6 Tax 0.4 1.8 Profit for the year 7.5 13.4 Basic earnings per share 2.3p 4.2p Diluted earnings per share 2.3p 4.4p All activity arose from continuing operations.
Basis of preparation The financial information contained in this appendix is pro-forma and does not constitute full statutory accounts within the meaning of section 435 of the Companies Act 2006.
The information has been extracted from the records of BTG plc and Biocompatibles International plc, combining the results of both companies for the years ended 31 March 2011 and 31 March 2010.
The information has been prepared using the accounting policies and basis of preparation set out in note 2 to the Group financial statements, except that, for comparative purposes, the following items have been excluded from the pro-forma information: Amortisation of business combination intangibles: Effect of fair value adjustments on inventory arising from IFRS3 Business Combinations: One-off transaction related expenses and reorganisation costs: Impact of deferred tax asset and liabilities recognised upon acquired intangible assets: Impact of US tax-free reorganisation, which resulted in a one-off deferred tax asset of 18.6m being recognised in the year ended 31 March 2011.
135 BTG plc Annual Report and Accounts 2011 Financials
